Secure Communities is optional, Harris says

SAN FRANCISCO — California Atty. Gen. Kamala Harris told local law enforcement agencies Tuesday that they were not obligated to comply with a federal program whose stated goal is to deport illegal immigrants convicted of serious crimes.

It was Harris' first public assessment of Secure Communities. Under the program launched in 2008, all arrestees' fingerprints are sent to immigration officials, who may ask police and sheriff's departments to hold suspects for up to 48 hours after their scheduled release so they can be transferred to federal custody.

Although the intent may have been to improve public safety, Harris said that a review of data from March through June showed that 28% of those targeted for deportation in California as a result were not criminals. Those numbers, she noted, had changed little since U.S. Immigration and Customs Enforcement a year earlier pledged to reform the program to focus on the most serious offenders.

"Secure Communities has not held up to what it aspired to be," Harris said. The law enforcement bulletin she issued Tuesday stated that "immigration detainer requests are not mandatory, and each agency may make its own decision" about whether to honor them.

Harris said her office conducted its analysis after dozens of agencies across the state inquired about whether they were compelled to honor the ICE requests.

Some elected officials and local law enforcement have complained that — in addition to pulling in those found guilty of minor offenses or never convicted — Secure Communities had made illegal immigrants fearful of cooperating with police, even when they were the victims.

Harris, a former prosecutor, echoed that view Tuesday.

"I want that rape victim to be absolutely secure that if she waves down an officer in a car that she will be protected … and not fear that she's waving down an immigration officer," Harris said

While immigrant-rights advocates applauded her announcement, they said it did not go far enough. Allowing police chiefs and sheriffs to craft their own policies without state guidance, they said, could lead to disparate enforcement and enable racial profiling.

This "should eliminate the confusion among some sheriffs about the legal force of detainers," said Reshma Shamasunder, executive director of the California Immigrant Policy Center. "The only logical next step is a strong, statewide standard that limits these burdensome requests."

One attempt by legislators to do just that unraveled in October with Gov. Jerry Brown's veto of the Trust Act. The proposed law by Assemblyman Tom Ammiano (D-San Francisco) would have forbidden police departments to honor federal detainer requests except in cases in which defendants had been convicted of a serious or violent crime.

Ammiano on Monday reintroduced a modified version of the measure. Harris said she had opposed the bill's last iteration for going "too far" and had not seen the current version, but looked forward "to working with the governor and any of our lawmakers to take a look at what we can do to improve consistency."

"It's very difficult to create formulas for law enforcement," she said, noting that local agencies should have the freedom to determine which federal hold requests to honor. For example, she said, an inmate with five previous arrests for forcible rape but no convictions might still be deemed too great a risk for release.

Some law enforcement agencies, including the San Francisco Sheriff's Department and the Santa Clara County Sheriff's Department, have declined to comply with federal requests to hold non-serious offenders. Los Angeles Police Chief Charlie Beck followed suit last month, announcing that suspected illegal immigrants arrested in low-level crimes would no longer be turned over for possible deportation.

Los Angeles County Sheriff Lee Baca, who opposed the Trust Act, is among those who have argued that compliance with Secure Communities was mandatory.

On Tuesday, Los Angeles County sheriff's spokesman Steve Whitmore said that Harris' opinion was welcome guidance that may offer sheriffs more flexibility in how they deal with immigration detainees.

"The attorney general's opinion is going to be taken very seriously," Whitmore said. "The sheriff applauds it and is grateful for it." Baca, he added, has been working with the attorney general and the governor on the issue.

In a written response to Harris' announcement, a spokeswoman for Immigration and Customs Enforcement said the agency's top priorities were the deportation of criminals, recent border-crossers and repeat violators of immigration law.

"The federal government alone sets these priorities and places detainers on individuals arrested on criminal charges to ensure that dangerous criminal aliens and other priority individuals are not released from prisons and jails into our communities," the statement said.

lee.romney@latimes.com

cindy.chang@latimes.com

Romney reported from San Francisco and Chang from Los Angeles.

Read More..

Know What You'll Look Like in 30 Years — Maybe Then You'll Max Out Your 401(k)

Don’t think you’ll ever get old? Keith Richards probably didn’t either. But at least he had a retirement plan.

Chances are good, however, that you’re not saving enough for your retirement. To convince you to sock away enough gold for your golden years, Merrill Edge has launched an online magic mirror to remind you that you won’t be forever young.

Face Retirement lives up to the catty double meaning in its name. Using a facial aging algorithm, the web app snaps a photo of you with your laptop’s camera and then shows you what you’ll look like at 47, 57, 67 and so on, all the way to 107.

The wrinkly, saggy results aren’t pretty. And that’s the point.

In a 2011 study cited by Merrill Edge (Merrill Lynch’s online discount brokerage), Stanford behavioral economics researchers say that we’re often reluctant to save for retirement because deep down we don’t identify with that older person we’ll one day be: “To people estranged from their future selves, saving is like a choice between spending money today or giving it to a stranger years from now.”

To find out if they could alter that perception, the researchers immersed test subjects into a virtual reality simulation that showed them a computer-generated vision of themselves at retirement age and then asked them questions about money. The study found that “those who interacted with their virtual future selves exhibited an increased tendency to accept later monetary rewards over immediate ones.” In other words, they were willing to save more.

Merrill Edge’s app isn’t as sophisticated as the Stanford version, but the results are still unnerving. The site’s other scare tactic involves charting increased cost-of-living projections alongside your gravity-ravaged face. In 2042, a loaf of bread is expected to cost more than $6. In 2082, a gallon of gas could cost nearly $40.

If those figures are anywhere close to right, the majority of us could be in trouble. According to new figures from the Boston College Center for Retirement Studies, more than half of U.S. households aren’t on track to maintain their current standard of living by retirement. Low savings rates could play a role in that, but the study puts much of the blame on falling interest rates and the bursting of the housing bubble, which itself was driven by excessive optimism that home prices would climb forever. When it comes to magical thinking, turns out retirement isn’t the only thing we get wrong.

Read More..

Lady Gaga buys Michael Jackson’s costumes at auction

LOS ANGELES (Reuters) – Pop star Lady Gaga purchased 55 items belonging to late singer Michael Jackson in a weekend auction that raised more than $ 5 million, a portion of which will be donated to charity, Julien’s Auctions said.

The auction, held in Beverly Hills, showcased 465 lots of items spanning Jackson’s career through the years, including costumes and props used on tour and in music videos.

Highlights from the sale included the late singer’s “BAD” tour jacket raising $ 240,000, a white glove selling for $ 192,000 and one of the singer’s Pepsi and Awards jacket garnering more than $ 68,000, the auction house said in a statement.

Following Sunday’s auction, Gaga told her 31 million Twitter followers that “the 55 pieces I collected today will be archived & expertly cared for in the spirit & love of Michael Jackson, his bravery, & fans worldwide.”

Jackson died aged 50 in June 2009 in Los Angeles from an overdose of the anesthetic propofol and sedatives.

The collection of outfits, designed by Los Angeles-based collaborators Dennis Tompkins and Michael Bush and gifted back to them by the late singer, were taken on a world tour earlier this year, traveling across South America, Europe and Asia.

In September, British hat designer Philip Treacy designed his first London fashion week show in a decade around Jackson’s auction costumes, which were worn by the models down the runway and accessorized with hats inspired by the late singer’s life.

Gaga not only attended Treacy’s show but was on hand to introduce the milliner’s collection.

The auction exceeded pre-sale estimates of $ 1 million to $ 2 million, and a portion of the final amount raised will benefit the Guide Dogs of America and Nathan Adelson Hospice in Las Vegas.

(Reporting By Piya Sinha-Roy, editing by Jill Serjeant)

Celebrity News Headlines – Yahoo! News

Read More..

Extended Use of Breast Cancer Drug Suggested

The widely prescribed drug tamoxifen already plays a major role in reducing the risk of death from breast cancer. But a new study suggests that women should be taking the drug for twice as long as is now customary, a finding that could upend the standard that has been in place for about 15 years.

In the study, patients who continued taking tamoxifen for 10 years were less likely to have the cancer come back or to die from the disease than women who took the drug for only five years, the current standard of care.

“Certainly, the advice to stop in five years should not stand,” said Prof. Richard Peto, a medical statistician at Oxford University and senior author of the study, which was published in The Lancet on Wednesday and presented at the San Antonio Breast Cancer Symposium.

Breast cancer specialists not involved in the study said the results could have the biggest impact on premenopausal women, who account for a fifth to a quarter of new breast cancer cases. Postmenopausal women tend to take different drugs, but some experts said the results suggest that those drugs as well might be taken for a longer duration.

“We’ve been waiting for this result,” said Dr. Robert W. Carlson, a professor of medicine at Stanford University. “I think it is especially practice-changing in premenopausal women because the results do favor a 10-year regimen.”

Dr. Eric P. Winer, chief of women’s cancers at the Dana-Farber Cancer Institute in Boston, said that even women who completed their five years of tamoxifen months or years ago might consider starting on the drug again.

Tamoxifen blocks the effect of the hormone estrogen, which fuels tumor growth in estrogen receptor-positive cancers that account for about 65 percent of cases in premenopausal women. Some small studies in the 1990s suggested that there was no benefit to using tamoxifen longer than five years, so that has been the standard.

About 227,000 cases of breast cancer are diagnosed each year in the United States, and an estimated 30,000 of them would be in premenopausal women with ER-positive cancer and prime candidates for tamoxifen. But postmenopausal women also take tamoxifen if they cannot tolerate the alternative drugs, known as aromatase inhibitors.

The new study, known as Atlas, included nearly 7,000 women with ER-positive disease who had completed five years of tamoxifen. They came from about three dozen countries. Half were chosen at random to take the drug another five years, while the others were told to stop.

In the group assigned to take tamoxifen for 10 years, 21.4 percent had a recurrence of breast cancer in the ensuing nine years, meaning the period 5 to 14 years after their diagnoses. The recurrence rate for those who took only five years of tamoxifen was 25.1 percent.

About 12.2 percent of those in the 10-year treatment group died from breast cancer, compared with 15 percent for those in the control group.

There was virtually no difference in death and recurrence between the two groups during the five years of extra tamoxifen. The difference came in later years, suggesting that tamoxifen has a carry-over effect that lasts long after women stop taking it.

Whether these differences are big enough to cause women to take the drug for twice as long remains to be seen.

“The treatment effect is real, but it’s modest,” said Dr. Paul E. Goss, director of breast cancer research at the Massachusetts General Hospital.

Tamoxifen has side effects, including endometrial cancer, blood clots and hot flashes, which cause many women to stop taking the drug. In the Atlas trial, it appears that roughly 40 percent of the patients assigned to take tamoxifen for the additional five years stopped prematurely.

Some 3.1 percent of those taking the extra five years of tamoxifen got endometrial cancer versus 1.6 percent in the control group. However, only 0.6 percent of those in the longer treatment group died from endometrial cancer or pulmonary blood clots.

“Over all, the benefits of extended tamoxifen seemed to outweigh the risks substantially,” Trevor J. Powles of the Cancer Center London, said in a commentary published by The Lancet.

Dr. Judy E. Garber, director of the Center for Cancer Genetics and Prevention at Dana-Farber, said many women have a love-hate relationship with hormone therapies.

Read More..

ENI Announces Major Gas Find Off Mozambique

LONDON — The Italian oil company ENI said Wednesday that it had made new natural gas discoveries in the waters off Mozambique, a find that will help consolidate ENI’s position as one of the leaders in the hot new East Africa region.

Offshore Mozambique, where ENI’s discovery is located, ranked third in the world in terms of oil and gas discovered last year, after the Santos Basin in Brazil and Iraqi Kurdistan, according to Mansur Mohammed, an analyst at Wood Mackenzie in Edinburgh.

The finds — from the sixth and seventh wells that ENI has drilled — add an additional 6 trillion cubic feet of gas to what ENI has already found. That is a large amount of gas but is dwarfed by the 68 trillion cubic feet that ENI now says it has found in its exploration concession called Block 4, where ENI has a 70 percent shareholding.

Three other shareholders — Galp Energia of Portugal, Kogas of South Korea and ENH, the Mozambican national oil company — each hold 10 percent.

The total amount discovered is equivalent to about 12 billion barrels of oil. A high proportion is likely to be recoverable, ENI said.

According to industry estimates, ENI’s share of the Mozambique discoveries could be worth around $15 billion.

The ENI finds coincide with an effort by the company’s chief executive, Paolo Scaroni, to focus more on exploration and production. In an interview, Mr. Scaroni said that ENI’s exploration activities in Mozambique would come to about $700 million. When you make a business of exploration and are “successful you make a huge amount of money,” he said.

ENI first found gas in Mozambique last year, closely following a discovery by Anadarko Petroleum of the United States.

The two companies are now negotiating with the government on a development plan. The biggest money earner is likely to be exporting gas to Asia as liquefied natural gas. The Web site of the Mozambique Instituto Nacional de Petroleo, the energy ministry, has a presentation that indicates that as many as 10 LNG plants or trains could be built, which would make Mozambique a very large player in the world gas market.

Mr. Scaroni said there could also be a role for a floating LNG facility, a technology that Royal Dutch Shell is now developing for use off western Australia. Shell recently tried to buy Cove Energy, which had a small position in the Mozambique discoveries, but was outbid by Thailand’s PTT Exploration and Production.

ENI is not a major player in LNG and may need help with the huge capital costs for developing the gas, which Mr. Scaroni put in the “tens of billions” of dollars.

Anadarko is also not an LNG specialist. It is widely thought in the industry that the companies will bring in partners.

Mr. Scaroni said he had been talking to potential partners “but we are fairly reluctant to strike a deal with anybody until we finish our exploration.”

A recent report by Bernstein Research says that Mozambique will be “ENI’s most significant project, although we do not expect production until 2019 at the earliest.” Bernstein estimates that the internal rate of return for Mozambique LNG will be a substantial 27 percent.

The gas discoveries off Mozambique are contained in sandstone deposits in what were ancient river beds, similar to those off West Africa and elsewhere.

What makes the Mozambique discoveries particularly rich is that the sandstone layers containing the gas are particularly thick. One of the wells ENI drilled, called Coral 2 found gas-bearing rock 140 meters, or almost 460 feet, thick — an exceptional amount.

“Mozambique is a very positive exploration story,” Mr. Mohammed of Wood Mackenzie said. “We are talking about an unprecedented high exploration success rate that transformed the outlook for the region.”

This article has been revised to reflect the following correction:

Correction: December 5, 2012

An earlier version of this article misspelled the first name of ENI’s chief executive. He is Paolo Scaroni, not Paulo.

Read More..

Mexico port picks up slack from strike at L.A., Long Beach complex

ENSENADA — This sluggish port city is coming alive.

Standing atop a pier with a hulking cargo ship behind him, dock manager Rogelio Valenzuela Gonzalez motioned Monday toward four cranes as they plucked metal containers from the vessel.

Operators swiveled the cranes toward a line of flatbed trucks. Supervisors in reflective vests and hard hats watched from below, using two-way radios to dispatch trucks as they filled up.

Not even during the peak fall shipping season is this port so busy.

But a strike that has effectively shut down rival ports in Los Angeles and Long Beach has diverted ships south of the border. It has become a windfall for the port located about 50 miles from the border, its workers and the region's struggling economy.

"It's good for the workers' families," said Gonzalez, adding that the extra work will pay for additional Christmas presents. "We all know it's temporary, but it definitely helps out at the end of the year."

The Southern California strike ended its first week Monday, with negotiations continuing but no signs of an immediate resolution.

The strike by the International Longshore and Warehouse Union Local 63 Office Clerical Unit, which handles paperwork for incoming and outgoing ships, has crippled the nation's two busiest cargo ports.

The dispute centers on the charge by the union that employers — large shipping lines and terminal operators — have steadily outsourced jobs through attrition. The union says the employers have transferred work from higher-paid union members to lower-paid employees in other states and countries.

The employers dispute that claim, saying they've offered the workers full job security and generous wage and pension increases. Though the union has only 800 members, the 10,000-member dockworkers union is honoring the picket lines.

Economists estimate the effect of the work stoppage at $1 billion a day in forfeited worker pay, missing revenue for truckers and other businesses and the value of the cargo that hasn't been able to reach its destination. The two ports are directly responsible for an estimated 595,000 jobs in Southern California.

But while thousands of Southern California workers sit idle in Los Angeles and Long Beach, the walkout is giving Ensenada a hoped-for chance to showcase itself.

Collectively, Los Angeles and Long Beach handle 100 times more cargo each year than Ensenada.

Long seen as a backup port, Ensenada is eager to win more business from shippers inconvenienced by the second major work dispute at the L.A. and Long Beach ports in a decade.

"It's a great opportunity to show that the Port of Ensenada presents an alternative method for bringing in products from Asia and the Pacific Rim," said Kenn Morris, president of Crossborder Group, a San Diego consulting firm. "The Ensenada port can really show itself off as being something a lot of people hadn't expected."

Uncertain how long the strike may last, retailers have scrambled to find alternate ways to get their products onto shelves. Given their typically thin profit margins, retailers are concerned about the added shipping costs.

"These blockages are dead-weight losses to the system," said Carl Voigt, an international business professor at USC. "They raise costs for everybody. Everybody's goods and services are more expensive."

Ensenada is used to seeing the occasional cruise ship and maybe half a dozen cargo ships a week. Two ships have made unplanned dockings and unloaded cargo here in the last week. Three others have docked in Manzanillo, a Mexican port city 1,200 miles to the south of Ensenada.

Altogether, 17 ships bound for the L.A. or Long Beach port have been diverted elsewhere, including nine to Oakland, one to Mazatlan, Mexico, and one to Panama.

In Ensenada, dockworkers made quick work unloading 100 cargo containers from the Maersk Merlion. The giant cargo vessel was diverted over the weekend and docked early Monday morning.

Since late last week, Ensenada has been preparing for a hoped-for influx of diverted ships. The port has 200 dockworkers when operating at capacity, and an additional hundred clerical and customs workers.

Equipment is on standby. Workers are at the ready. And trucking lines have been placed on alert that cargo may need to be hauled.

"It's hard to guess how many ships we'll receive, but we are preparing for more," said Juan Carlos Ochoa, the port's trade development manager.

Ensenada is still handicapped by longer-standing obstacles, primarily its lack of railway access to move goods.

And for now, the cargo unloaded from the Maersk Merlion will sit at the port as the shipping line weighs whether to move it by truck to its final destination or have another ship pick up the containers at a later date.

The strike "is an extraordinary situation," Gonzalez said. "But it'll show our clients that this port is a good option. It's efficient, reliable and secure."

ricardo.lopez2@latimes.com

walter.hamilton@latimes.com

Lopez reported from Ensenada, and Hamilton from Los Angeles.

Read More..

NASA's Giant New Rocket Goes Supersonic (In a Wind Tunnel)

NASA has a big new rocket in the works, one designed to carry astronauts beyond earth orbit for the first time since the Saturn V took us to the moon. The Space Launch System will, among other things, make a trip to an asteroid, but before it can do that it must make a few trips to the wind tunnel.

The rocket’s first mission beyond earth orbit isn’t expected until 2017, assuming the program doesn’t fall off a fiscal cliff. Right now, NASA engineers are busy finalizing the design of the launch vehicle, testing a 10-foot model in the agency’s transonic tunnel in Langley, Virginia.

“The test includes the largest integrated vehicle model to be tested in a wind tunnel for SLS,” says John Blevins, SLS Lead Engineer for Aerodynamics and Acoustics. “It will simulate the environment of transonic flight that the SLS rocket will navigate during its flight.”

The model will be exposed to speeds up to Mach 1.2. There are 360 pressure transducers spread across the surface of the model, and data is acquired at a rate of thirteen thousand scans per second, according to NASA. The information gleaned from the wind tunnel tests will provide insight into the structural forces the SLS will endure during launch and acceleration from subsonic to supersonic flight.

The first mission will see the SLS launch the Orion spacecraft into lunar orbit as an initial check of the system. It will be an unmanned flight, but NASA hopes to fly astronauts around the moon by 2021 and expand the flight envelope of its new generation of space vehicles.

The Orion capsule has endured numerous kinds of testing in recent years, but it hit a bit of a speed bump recently when small cracks were found in the capsule slated for flight in 2017. The three hairline cracks, each less then two inches long, are located on the bottom of the vehicle. This capsule is expected to be used for a test flight to earth orbit atop a Delta IV rocket in 2014, three years before the SLS will launch an Orion into lunar orbit.

The cracks did not penetrate the aluminum skin of the Orion spacecraft. NASA says a simple fix will distribute the stress across the location where the cracks occurred according to the Denver Post.

“For this flight, since its unmanned, we can fix it and fly it” Orion program manager Mark Geyer told the newspaper. “When we build the one we’re actually going to put people on, we’ll make sure to fix this design.”

With NASA handing off the job of delivering astronauts and cargo to low earth orbit over to commercial companies like SpaceX and Orbital Sciences, the manned space program at the agency is focusing on exploration a bit deeper into space. Orion will be able to carry a four person crew on mission lasting up to 210 days. In addition to possible missions to an asteroid, Orion is also being designed for trips to the moon and Mars. For all trips the capsule would just be part of the space vehicle needed as was the case with the Apollo capsules which used a command module and lunar module for the missions.

Read More..

“Boardwalk Empire” creator on legalizing drugs and making Nucky likeable again

NEW YORK (TheWrap.com) – The prohibition drama “Boardwalk Empire” wrapped its spectacular third season Sunday night just weeks after the states of Colorado and Washington voted to legalize marijuana.

To “Boardwalk” creator Terence Winter, who has immersed himself in the history of prohibition to research his gangster epic, the votes feel like a move in the right direction.

“It’s great. I think they should legalize drugs in general,” Winter told TheWrap. “The war on drugs is clearly not working, and I think they should take the profit motive out of being a drug dealer. And maybe kids will go to college and do something else.”

Winter, who reassembled his writers a few weeks ago to begin work on the show’s fourth season, talked to us about whether they ever go out of their way to slow down the action, making Nucky Thompson (Steve Buscemi) likable again, and whether things are worse today than they were in the 1920s.

TheWrap: Is ‘Boardwalk’ making a case for drug legalization?

Winter: Well, I think history made it for us with prohibition. We’re just reflecting the reality of how it went down. I’m not trying to bend the reality or the truth of what happened. It clearly didn’t work. I don’t think people were more disposed to drink when alcohol was legal.

Actually, it had the opposite effect. Women didn’t start drinking until prohibition was enacted and college students didn’t start drinking until prohibition was enacted. Leaving the mystery aside might have had a better impact on the country – keeping it legal. In my personal opinion I don’t think making drugs legal would make anybody more likely to become a heroin addict, for example.

This is going to sound strange, but I mean it as a compliment. “Boardwalk” has a way of lulling you into looking at the costumes, and listening to the dialogue, and marveling at how pretty everything is. There are times when I almost want to nod off, it’s so comforting – and then suddenly someone gets set on fire. I feel you’re making a conscious effort to use boredom to really shock us at other times. Do you ever put in a scene that’s deliberately slow?

No, we don’t. I would disagree and say – slow or boring – there is dialogue that needs to be attended to and I think you need to pay attention to what’s going on. The pacing can sometimes be slower than certainly an action scene or a scene with incredible violence. Because we have such wide-ranging characters and such wide-ranging circumstances, some things might seem slower by comparison.

Obviously a scene involving a political figure or Margaret’s storyline, as opposed to something Al Capone is doing, is just by the very nature of it going to feel slow. But no, none of it is done by design.

I mean it in a good way. If you think things are slowing down, they’re not. It’s almost a trick.

The audience is so wide-ranging, too. We have people who can’t stand the violence and they’re much more entertained by the family stuff. One person’s slow is another person’s fascinating.

With the final episodes we got to see Nucky become really likable again. He’s always been generous, but at times he seemed a little too caught up in himself to care about the people around him. Was there an effort to make him a good guy again?

One of the points of this season is that he does get caught up in himself. That all comes home to visit in a big way in episode 11. He doesn’t know anything about Eddie Kessler the guy who works really closely with him. He doesn’t know if he has a family. He doesn’t know Chalky White’s phone number. It becomes apparent that he’s spent way too much time concerned with himself and his own affairs.

If you depict any character honestly, and show all of their colors, you’re going to find something relatable or likeable with anybody. And that’s certainly the truth with Al Capone or Luciano or Tony Soprano or any other famous character.

And certainly Steve Buscemi has an inherent likable quality to him. So when you add that to the mix you can’t help but like the guy.

Imagery is so important to the show, and I feel like at one point this season you did something just because it was gorgeous. When Billie changes her hair color to blonde, was there any reason to do that besides how incredible it looked in the explosion?

Well, she was sort of finally coming to terms with who she really was. That was the episode where she dropped the façade of Billie Kent and told Nucky her real name. She was going through a metamorphosis and that sort of illustrated that a little bit. They were sort of not pretending with each other any more.

Is Billie a natural blonde?

That color wasn’t natural. She wasn’t being Billie Kent that night. She was being the real person underneath. … But I agree it did look great in the explosion. Meg Chambers Steedle, who plays Billie Kent, is absolutely one of those people the camera just falls in love with. Unfortunately the context was terrible. But it was extremely cinematic.

Harrow kind of became the hero of the show this season. His scene of taking down the entire house full of gangsters: Wow. We’ve always been fascinated with the character and for me this season I was more interested in seeing who he is as a person and seeing him take that journey and fall in love and really explore that side of him. Given the way the story was, we knew it would end in violence.

But following the trajectory from the end of season 2, we knew this guy was very loyal to Jimmy and Angela and we knew he would stick around and take care of that kid. And of course Gillian being who she is, it wasn’t going to end well.

Is Gillian kaput at this point? The last time we saw her she was in a heroin daze, and she’s kind of lost everything.

She will be back on the show. She’s certainly still alive.

Is there anybody on the show you think you can’t kill?

Nope. Everybody’s up for grabs and that’s from the top on down. Anything can happen.

We hear so much about how much trouble our country is in. Do you think things are worse than they were in the 1920s?

No, and if anything, reading about how bad things were in the 1920s is strangely comforting in terms of how we think about things today. The level of corruption and the whole idea of going to hell in a hand basket is certainly nothing new. You look back and think, this pales in comparison. I think the more things change the more they stay the same.

TV News Headlines – Yahoo! News

Read More..

Generic Drug Makers Facing Squeeze on Revenue

They call it the patent cliff.

Brand-name drug makers have feared it for years. And now the makers of generic drugs fear it, too.

This year, more than 40 brand-name drugs — valued at $35 billion in annual sales — lost their patent protection, meaning that generic companies were permitted to make their own lower-priced versions of well-known drugs like Plavix, Lexapro and Seroquel — and share in the profits that had exclusively belonged to the brands.

Next year, the value of drugs scheduled to lose their patents and be sold as generics is expected to decline by more than half, to about $17 billion, according to an analysis by Crédit Agricole Securities.“The patent cliff is over,” said Kim Vukhac, an analyst for Crédit Agricole. “That’s great for large pharma, but that also means the opportunities theoretically have dried up for generics.”

In response, many generic drug makers are scrambling to redefine themselves, whether by specializing in hard-to-make drugs, selling branded products or making large acquisitions. The large generics company Watson acquired a European competitor, Actavis, in October, vaulting it from the fifth- to the third-largest generic drug maker worldwide.

“They are certainly saying either I need to get bigger, or I need to get ‘specialer,’ ” said Michael Kleinrock, director of research development at the IMS Institute for Healthcare Informatics, a health industry research group. “They all want to be special.”

As one consequence of the approaching cliff, executives for generic drug companies say, they will no longer be able to rely as much on the lucrative six-month exclusivity periods that follow the patent expirations of many drugs. During those periods, companies that are the first to file an application with the Food and Drug Administration, successfully challenge a patent and show they can make the drug win the right to sell their version exclusively or with limited competition.

The exclusivity windows can give a quick jolt to companies. During the first nine months of 2012, sales of generic drugs increased by 19 percent over the same period in 2011, to $39.1 billion from $32.8 billion, according to Michael Faerm, an analyst for Credit Suisse. Sales of branded drugs, by contrast, fell 4 percent during the same period, to $174.2 billion from $181.3 billion.

But those exclusive periods also make generic drug makers vulnerable to the fickle cycle of patent expiration. “The only issue is it’s a bubble, too,” said Mr. Kleinrock. He said next year, the generic industry would enter a drought that was expected to last about two years.  Of the drugs that are becoming generic, fewer have exclusivity periods dedicated to a single drug maker.

In 2013, for example, the antidepressant Cymbalta, sold by Eli Lilly, is scheduled to be available in generic form. But more than five companies are expected to share in sales during the first six months, according to a report by Ms. Vukhac.

Heather Bresch, the chief executive of Mylan, the second-largest generics company in the United States, said Wall Street analysts were obsessed with the issue. “I can’t go anywhere without being asked about the patent cliff, the patent cliff, the patent cliff,” she said. “The patent cliff is one aspect of a complex, multilayered landscape, and I think each company is going to face it differently.”

Jeremy M. Levin, the chief executive of Teva Pharmaceuticals, the largest global maker of generic drugs, agreed. “The concept of exclusivity — where only one generic player could actually make money out of the unique moment — has diminished,” he said. “In the absence of that, many companies have had to really ask the question, ‘How do I really play in the generics world?’ ”

For Teva, Mr. Levin said, he believes the answer will be both its reach  — it sells 1,400 products, and one in six generic prescriptions in the United States is filled with a Teva product  — and what he says is a reputation for making quality products. That focus will be increasingly important, he said, given recent statements by the F.D.A. that it intends to take a closer look at the quality of generic drugs. Mr. Levin also said he planned to cut costs, announcing last week that he intended to trim from $1.5 to $2 billion in expenses over the next five years.

Read More..

Generic Drug Makers Facing Squeeze on Revenue

They call it the patent cliff.

Brand-name drug makers have feared it for years. And now the makers of generic drugs fear it, too.

This year, more than 40 brand-name drugs — valued at $35 billion in annual sales — lost their patent protection, meaning that generic companies were permitted to make their own lower-priced versions of well-known drugs like Plavix, Lexapro and Seroquel — and share in the profits that had exclusively belonged to the brands.

Next year, the value of drugs scheduled to lose their patents and be sold as generics is expected to decline by more than half, to about $17 billion, according to an analysis by Crédit Agricole Securities.“The patent cliff is over,” said Kim Vukhac, an analyst for Crédit Agricole. “That’s great for large pharma, but that also means the opportunities theoretically have dried up for generics.”

In response, many generic drug makers are scrambling to redefine themselves, whether by specializing in hard-to-make drugs, selling branded products or making large acquisitions. The large generics company Watson acquired a European competitor, Actavis, in October, vaulting it from the fifth- to the third-largest generic drug maker worldwide.

“They are certainly saying either I need to get bigger, or I need to get ‘specialer,’ ” said Michael Kleinrock, director of research development at the IMS Institute for Healthcare Informatics, a health industry research group. “They all want to be special.”

As one consequence of the approaching cliff, executives for generic drug companies say, they will no longer be able to rely as much on the lucrative six-month exclusivity periods that follow the patent expirations of many drugs. During those periods, companies that are the first to file an application with the Food and Drug Administration, successfully challenge a patent and show they can make the drug win the right to sell their version exclusively or with limited competition.

The exclusivity windows can give a quick jolt to companies. During the first nine months of 2012, sales of generic drugs increased by 19 percent over the same period in 2011, to $39.1 billion from $32.8 billion, according to Michael Faerm, an analyst for Credit Suisse. Sales of branded drugs, by contrast, fell 4 percent during the same period, to $174.2 billion from $181.3 billion.

But those exclusive periods also make generic drug makers vulnerable to the fickle cycle of patent expiration. “The only issue is it’s a bubble, too,” said Mr. Kleinrock. He said next year, the generic industry would enter a drought that was expected to last about two years.  Of the drugs that are becoming generic, fewer have exclusivity periods dedicated to a single drug maker.

In 2013, for example, the antidepressant Cymbalta, sold by Eli Lilly, is scheduled to be available in generic form. But more than five companies are expected to share in sales during the first six months, according to a report by Ms. Vukhac.

Heather Bresch, the chief executive of Mylan, the second-largest generics company in the United States, said Wall Street analysts were obsessed with the issue. “I can’t go anywhere without being asked about the patent cliff, the patent cliff, the patent cliff,” she said. “The patent cliff is one aspect of a complex, multilayered landscape, and I think each company is going to face it differently.”

Jeremy M. Levin, the chief executive of Teva Pharmaceuticals, the largest global maker of generic drugs, agreed. “The concept of exclusivity — where only one generic player could actually make money out of the unique moment — has diminished,” he said. “In the absence of that, many companies have had to really ask the question, ‘How do I really play in the generics world?’ ”

For Teva, Mr. Levin said, he believes the answer will be both its reach  — it sells 1,400 products, and one in six generic prescriptions in the United States is filled with a Teva product  — and what he says is a reputation for making quality products. That focus will be increasingly important, he said, given recent statements by the F.D.A. that it intends to take a closer look at the quality of generic drugs. Mr. Levin also said he planned to cut costs, announcing last week that he intended to trim from $1.5 to $2 billion in expenses over the next five years.

Read More..